Volume 18 Issue 7, July 2018

Wang, Leite de Oliveira et al. show that BRAF^V600E-mutant melanomas that are resistant to BRAF and MEK inhibitors are vulnerable to increased levels of reactive oxygen species and that this can be exploited therapeutically using a histone deacetylase inhibitor.

A recent study published in Science Translational Medicine generated a mouse model to study the link between surgical wounding and distant tumour growth, showing that the systemic wound healing response induced by surgery can promote tumour growth.

Roerink et al. have used organoids derived from multiple single cells of colorectal cancers from three patients as well as from normal colorectal epithelium of the same patients to comprehensively study intratumoural heterogeneity.

Single-cell RNA sequencing analysis in paediatric diffuse midline gliomas with histone H3 lysine 27 to methionine mutations indicates that these aggressive tumours contain many stem-like cells and that lineage-based therapeutic targeting might be beneficial.

In this Review, Drost and Clevers discuss the recent advances in organoid models of cancer and how they can be exploited to drive the translation of basic cancer research into novel patient-specific treatment regimens in the clinic.

In this Opinion article, Twumasi-Boateng et al. discuss the use of oncolytic viruses as multiplexed immune-modulating platforms with the potential to improve the effectiveness of immunotherapies through novel synergistic mechanisms promoting antitumour immune activity.

In this Opinion article, Seluanov et al. discuss the diverse mechanisms of cancer resistance found in long-lived mammals and argue that studies of unconventional long-lived and cancer-resistant animal species could provide breakthroughs in cancer therapy and prevention.

This Opinion discusses studies indicating a direct role of RB in chromatin regulation and DNA repair. The authors propose that a non-canonical RB pathway exists, which is independent of the function of RB in cell cycle regulation and which contributes to cancer progression.

This Opinion argues for a new look at the role of ABC transporters in cancer multidrug resistance to push forward their clinical application as biomarkers and as targets in combination therapies in order to improve anticancer drug efficiency.